Samsung Epis (KRX:0126Z0) said its unit Samsung Bioepis signed a $420 million partnership deal with Switzerland-based Teva Pharmaceuticals International to commercialize two biosimilar drugs in the US, according to a Friday filing with the Korea Exchange.

Under the deal, Samsung Bioepis will develop, manufacture, and supply SB2, a biosimilar to Remicade used in the treatment of Crohn's disease, ulcerative colitis, and rheumatoid arthritis, and SB4, a biosimilar to Enbrel used in the treatment of rheumatoid arthritis, psoriatic arthritis, and psoriasis.

Teva will handle US commercialization while sharing sales profits with Samsung Bioepis under a deal structure that includes up to $75 million in upfront payments, $75 million in launch milestones, and $270 million in sales milestones.